PharmacovigilanceOfficial

EMA publishes PSUSA outcome for cytomegalovirus immunoglobulin: marketing authorisations to be maintained

🇪🇺 EMA · Thu 19 Nov 2026

The EMA has published the outcome of a periodic safety update report single assessment for cytomegalovirus immunoglobulin, with the regulatory outcome recorded as maintenance.

The European Medicines Agency (EMA) published on 19 November 2026 the outcome of procedure PSUSA/00000914/202601, a periodic safety update report single assessment covering the active substance cytomegalovirus immunoglobulin.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.